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Abstract
Background: Ischemic stroke is the fifth leading cause of death in the US. Clinical 
techniques aimed at helping to reduce the morbidity associated with stroke have 
been studied extensively, including therapeutic hypothermia. In this study, the 
authors review the literature regarding the role of therapeutic hypothermia in 
ischemic stroke to appreciate the evolution of hypothermia technology over several 
decades and to critically analyze several early clinical studies to validate its use 
in ischemic stroke.
Methods: A comprehensive literature search was performed using PubMed and 
Google Scholar databases. Search terms included “hypothermia and ischemic 
stroke” and “therapeutic hypothermia.” A comprehensive search of the current 
clinical trials using clinicaltrials.gov was conducted using the keywords “stroke and 
hypothermia” to evaluate early and ongoing clinical trials utilizing hypothermia in 
ischemic stroke.
Results: A comprehensive review of the evolution of hypothermia in stroke and 
the current status of this treatment was performed. Clinical studies were critically 
analyzed to appreciate their strengths and pitfalls. Ongoing and future registered 
clinical studies were highlighted and analyzed compared to the reported results 
of previous trials.
Conclusion: Although hypothermia has been used for various purposes over 
several decades, its efficacy in the treatment of ischemic stroke is debatable. 
Several trials have proven its safety and feasibility; however, more robust, 
randomized clinical trials with large volumes of patients are needed to fully establish 
its utility in the clinical setting.
Key Words: Endovascular, ischemic stroke, neuroprotection, neurovascular 
surgery, stroke, therapeutic hypothermia
INTRODUCTION
Stroke is a leading cause of disability in most 
industrialized countries and its economic burden is 
enormous. The American Heart Association/American 
Stroke Association currently considers stroke to be the 
fifth leading cause of death in the US. An estimated 
6.6 million Americans over the age of 20 have suffered 
a stroke. Projections show that, by 2030, an additional 
3.4 million people aged ≥18 years will have had a 
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stroke, which is a 20.5% increase in prevalence from 
2012.[41] Significant advancements have been made 
in the last few decades that have resulted in improved 
outcomes. Alteplase is the only US Food and Drug 
Administration‑approved medical treatment for acute 
ischemic stroke,[49] and its use doubled between 2005 and 
2009.[1] However, only one‑third of treated patients recover 
enough to be significantly free of disability. The recent 
publications of multiple trials have also shown potential 
benefit of intra‑arterial thrombectomy when done in a 
timely fashion.[4,22,32,47] Similar fast‑paced advances in 
research have not been witnessed in proving the benefit 
of hypothermia in patients suffering from ischemic 
stroke, even though the treatment shows promise. In this 
review, we discuss the historical perspective of therapeutic 
hypothermia, its mechanism of action, and early clinical 
trials utilizing hypothermia in ischemic stroke patients.
METHODS
A comprehensive literature search was performed 
using both the PubMed and Google Scholar databases 
to investigate the mechanism of action of therapeutic 
hypothermia in early animal studies. Search terms 
included “hypothermia and ischemic stroke” and 
“therapeutic hypothermia.” Full text versions of the 
papers included in the review were obtained and 
independently reviewed by both authors.
A comprehensive search of the recent and current clinical 
trials utilizing therapeutic hypothermia was performed 
through the clinicaltrials.gov database. Search terms used 
included “Stroke and Hypothermia.” Full text versions 
of the published trials were obtained and independently 
reviewed by the authors. Studies that were terminated 
early or aborted were omitted. Non‑English articles were 
omitted for this review. No contact was made with any of 
the authors of the papers included in this review.
THERAPEUTIC HYPOTHERMIA—WHERE IT 
ALL STARTED
Therapeutic hypothermia has been used for several years 
but there is some hesitation to its clinical adaptation 
worldwide because of the apparent high risk of 
complications. Only recently has the medical community 
begun to realize the benefits of therapeutic hypothermia, 
and its use is now widely propagated for various purposes.
For several decades, therapeutic hypothermia has been 
used to provide anesthesia during amputations, to 
prevent cancer cells from multiplying, and to reduce 
complications during heart surgery.[15,38] The first actual 
recorded clinical use of therapeutic hypothermia was in 
1937, when Fay “cooled” a patient to 32°C for 24 h, in 
a desperate attempt to prevent cancer cells from further 
multiplying and progressing at lower temperatures.[15,16] In 
1941, Smith and Fay reported that induced therapeutic 
hypothermia improved “the recovery of the conscious 
state of patients with brain injury,” reporting the findings 
in a large series of patients with severe head injury.[10] In 
1953, Bigelow and McBirnie demonstrated the beneficial 
effects of therapeutic hypothermia for the brain and 
heart during cardiac surgery in a canine model.[7] 
Neurosurgeons started using hypothermia for traumatic 
brain and spinal cord injury after the work done by 
Romsoff et al. showed that hypothermia reduced the 
brain volume, blood flow, and metabolic rate of a normal 
dog brain.[45,46] However, these advancements met hurdles 
in the shape of numerous complications that followed 
hypothermia, most notably ventricular fibrillation,[43] 
pulmonary complications,[51] acidosis,[8] and skin damage.
THERAPEUTIC HYPOTHERMIA FOR 
NEUROPROTECTION
Scientists have strived to reduce complication rates 
related to hypothermia because of the encouraging 
beneficial effects. Hence, the concept of hypothermia in 
some way inducing neuroprotection received significant 
attention in the last several decades, with studies 
examining this possibility being reported. At present, 
hypothermia is recognized as perhaps the most robust 
neuroprotectant in the laboratory to date. However, 
much of our current knowledge is derived from studies 
performed on cerebral injury models caused by cardiac 
arrest rather than stroke. Two large, randomized trials, 
one from Europe and the other from Australia, are 
now available that show substantial benefit of mild 
hypothermia on neurologic outcome after cardiac 
arrest. The Australian study showed that more patients 
in the hypothermic group had a favorable outcome 
compared to the normothermic group (49% vs. 26%; 
P = 0.046).[6] Similarly, the European study conducted 
by The Hypothermia After Cardiac Arrest Study 
Group demonstrated statistically significant improved 
outcome of the hypothermic group compared to the 
normothermic group (55% vs. 39%; P = 0.009).[30]
The molecular cascades that set in after an ischemic 
stroke are complex. In the acute stage, the decrease 
in cerebral blood flow disrupts ionic homoeostasis, 
leading to increased intracellular calcium and release of 
excitatory neurotransmitters. Intracellular edema also 
occurs when sodium and chloride flood the postsynaptic 
cell.[21] Accumulating intracellular calcium is sequestered 
by the mitochondria, which causes mitochondrial 
dysfunction, leading to free radical production, especially 
if reperfusion ensues. In the subacute stage, neuronal 
apoptotic and neuroinflammatory pathways are initiated 
hours to days after the ischemic onset. Cerebral ischemia 
leads to oxidative stress, excitotoxicity, and initiation of 
apoptotic pathways that lead to neuronal death.[11] These 
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post‑ischemic effects are exacerbated when the patient’s 
temperature increases by 0.5°C or more above 37°C.[13] 
In addition, it has been noted that the formation of free 
radicals and release of glutamate into the extracellular 
space are proportional to the temperature of the ischemic 
tissue.[3] Therefore, decreasing the body temperature 
will translate into sluggish ATP breakdown, leading to 
improved molecular homeostasis and the return of acid–
base balance to near‑physiologic levels.
HOW DOES HYPOTHERMIA WORK?
Various molecular mechanisms are alleged to be 
responsible for the beneficial effects of hypothermia in 
ischemic stroke. Some of the few biological mechanisms 
responsible for the therapeutic effect of hypothermia 
include the suppression of dopamine and glutamate 
release;[10] reduction in the number of α‑amino‑3‑
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
and N-Methyl-D-Aspartate (NMDA) receptors expressed 
on hippocampal neurons after global ischemia;[17] 
attenuation of neuronal apoptosis and reduced activity of 
prodeath signaling pathways such as p53;[31,36] reduction 
in the production and activity of some of the most potent 
proinflammatory mediators implicated in stroke, such as 
interleukin 1β, tumor necrosis factor α, interleukin 6,[20] 
matrix metalloproteinases (MMPs), specifically MMP-2 
and MMP-9;[23] and inhibition of nuclear factor κB.[24] 
Hypothermia has little effect on the core of the infarcted 
tissue, but acts on the tissue at risk in the penumbra. 
The penumbra provides an ideal environment for 
generation of free radicals such as hydroxyl (OH–), 
superoxide (O2–), and hydrogen peroxide (H2O2) that 
can cause substantial damage to cellular DNA and lipid 
membranes. Induction of hypothermia might dampen 
the generation of free radicals and ameliorate their 
deleterious effects.[20] Disruption of the blood–brain 
barrier (BBB) is a well-known phenomenon that follows 
ischemic stroke. Several studies have consistently shown 
that moderate brain hypothermia started soon after 
ischemic insult results in decreased leakiness of the BBB, 
hence preventing high concentrations of blood‑derived 
serine proteases and zymogen precursors from entering 
the brain, which can cause aberrant activation of serine 
protease signaling with deleterious consequences.[19,27,28] 
Hypothermia—given its multiple synergistic effects on 
ischemia and reperfusion—has shown great potential to 
be successful at the clinical level.
PRECLINICAL ANIMAL STUDIES
The development of relatively simple and reproducible 
animal models mimicking cerebral ischemia has led to 
numerous studies investigating the feasibility and efficacy 
of therapeutic hypothermia. Animal models of focal 
ischemia usually involve the permanent or reversible 
unilateral occlusion (for 1–3 hours) of the middle 
cerebral artery (MCA).[9] Despite major differences across 
animal studies, which include the model and duration of 
ischemia (temporary vs. permanent) and timing, duration, 
and depth of cooling,[50] hypothermia has shown favorable 
effects. However, these protective effects were seen in a 
more consistent and robust manner in models of temporary 
MCA occlusion (MCAO) than in permanent MCA 
occlusion. In their meta‑analysis, Van der Woop et al. 
reported a less robust effect of therapeutic hypothermia 
in the permanent MCAO model than that recorded with 
the temporary MCAO model,[34] whereas other studies 
showed that therapeutic hypothermia had no positive 
effect on infarct volume reduction in the permanent 
MCAO model.[36,39] One study model of transient MCAO 
showed 50% reduction in the size of infarct volume in 
hypothermic rats when hypothermia was induced 1 h after 
reperfusion.[53] Ridenour et al. showed that hypothermia 
yielded no benefits in animals that underwent permanent 
MCAO; however, in rats with temporary occlusion, the 
treatment reduced infarct volume by almost 50%, with 
a trend toward improved neurological function.[44] The 
effect of delayed intraischemic and postischemic cooling 
was also tested in animal models. One study reported 
that brain cooling to 32°C started at the same time as 
the 60‑min bilateral carotid artery occlusion decreased 
infarct volume by 75%, whereas delaying cooling for 
40 min eliminated protection.[40] Studies in animals have 
also demonstrated that hypothermia could be protective if 
applied once reperfusion has occurred.[29,52]
HUMAN STUDIES
Numerous human studies have been conducted 
over the past 2 decades investigating the potential 
therapeutic effects of hypothermia on neuroprotection 
and improvement in patient outcomes following both 
ischemic stroke and ischemic stroke with reperfusion. 
While numerous studies deserve recognition and 
mention, here, we discuss only those studies that 
played an important role in the history of therapeutic 
hypothermia.
In 1998, Schwab et al. published a feasibility and 
safety study of moderate hypothermia in patients with 
malignant MCA syndrome. Hypothermia to 33°C was 
induced within 14 h of stroke onset, and significant 
reductions in intracranial pressure were noted in all 
patients.[48] In this study, most deaths occurred during 
the rewarming phase because of a rebound increase in 
intracranial pressure. This study laid the foundation 
to the use of therapeutic hypothermia in patients with 
cerebral edema who do not respond to other medical 
therapies. The Copenhagen Stroke Study was a small 
case‑control study that was among the very first ones 
to focus on the use of therapeutic hypothermia for 
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neuroprotection in awake patients with acute ischemic 
stroke.[33] Patients had to present within 12 h of stroke 
onset and were cooled for 6 h. However, no difference in 
outcome or mortality at 6 months was noted.
Krieger et al. published the first phase of The Cooling 
for Acute Ischemic Brain Damage (COOL AID) study. 
This was a pilot study with an open design where authors 
attempted to demonstrate the feasibility and safety of 
hypothermia in patients with acute ischemic stroke. 
Hypothermia was induced by surface cooling utilizing 
cooling blankets for 12–72 h in patients presenting within 
6 h of symptom onset.[35] This trial showed that moderate 
therapeutic hypothermia in patients with acute ischemic 
stroke is feasible and can be done safely. The second phase 
of the COOL AID study was a randomized feasibility 
pilot trial assessing the safety of endovascular cooling in 
patients with acute ischemic stroke.[12] This study showed 
that the endovascular approach is a much more expedient 
way to cool patients than surface cooling. The trial also 
showed that shivering could be managed effectively with a 
combination of meperidine, buspirone, and skin warming, 
without intubation and sedation; however, no difference 
in outcome was seen between the two groups.
The Intravascular Cooling in the Treatment of 
Stroke (ICTuS) study was a safety and feasibility trial 
in which the use of an endovascular cooling system to 
achieve mild therapeutic hypothermia in awake, acute 
ischemic stroke patients was assessed; the results were 
similar to the COOL AID study.[37]
The Intravenous Thrombolysis Plus Hypothermia for 
Acute Treatment of Ischemic Stroke (ICTuS-L) study 
conducted in 2010 was a randomized controlled trial 
that assessed the safety and feasibility of therapeutic 
hypothermia using an endovascular cooling catheter in 
acute ischemic stroke patients presenting within 6 h of 
symptom onset. The study also tested the safety and 
feasibility of coupling therapeutic hypothermia with 
intravenous alteplase.[25] Patients were randomized into 
various groups depending on their time of presentation 
and whether they received alteplase and hypothermic 
treatments. No differences in mortality or 90‑day 
outcomes were reported; however, the incidence of 
pneumonia was significantly higher in the therapeutic 
hypothermia group, most likely due to immune 
suppression. The Intravascular Cooling in the Treatment 
of Stroke 2/3 (ICTuS2/3) trial, which was investigating 
long‑term outcomes of patients receiving hypothermia 
plus thrombolysis versus thrombolysis alone, was 
terminated in April 2015 and shall resume at a later time.
In an effort to investigate the effects of therapeutic 
hypothermia in a neurosurgical context, Els et al., in 
2006, showed that hemicraniectomy and hypothermia 
together resulted in better 6‑month functional outcomes 
based on the National Institutes of Health Stroke Scale 
(NIHSS) vs. hemicraniectomy alone in ischemic stroke 
patients with malignant cerebral edema.[14] Although 
the study included only 25 patients, the patients 
were randomized and no difference in side effects or 
complications were seen between the two groups.
Recently, Hong et al. also showed that 48 h of mild 
hypothermia and 48 h of rewarming following acute 
ischemic stroke led to a lower incidence of hemorrhagic 
transformation, a better outcome measured by the 
modified Rankin Score, and a lesser degree of malignant 
cerebral edema.[26] This study had a much larger number 
of patients treated with 75 total participants, which lent 
stronger credence to its conclusions. Keynote human 
studies are highlighted in Table 1.
EuroHYP-1, a European, multi-centered, phase III 
randomized controlled trial is currently recruiting 
participants in order to assess whether 24 h of induced 
hypothermia to 34–35°C coupled with best medical 
management results in a better 3‑month functional 
outcome vs. best medical management alone. The study 
is estimating its enrollment at 1500 participants, which 
would be one of the largest randomized controlled trials 
conducted to date on therapeutic hypothermia.
CLINICAL APPLICATION OF THERAPEUTIC 
HYPOTHERMIA
Timing and optimum temperature parameters
Although the optimum timing and duration of 
hypothermia in human beings is not clear, most active 
trials attempt to initiate cooling as close to stroke onset 
as possible. Different levels of hypothermia are defined; 
mild (>32°C), moderate (28−32°C), deep (20−28°C), 
profound (5−20°C), and ultraprofound (<5°C) 
hypothermia. Although the target temperature for cardiac 
arrest is 32–34°C, target temperature for neuroprotection 
is unknown. This question was tested in rats by Kollmar 
et al. who found substantial reduction in the infarct size. 
Furthermore, improvement in functional outcome was 
observed in the 33°C and 34°C groups compared with 
the other temperatures tested.[34] It is considered that, 
in clinical stroke, hypothermia may be a more effective 
strategy of neuroprotection if applied for a long duration 
after the ischemic event, however, no consensus has been 
reached in this matter.
Devices and techniques
Rapid advancements have been made in this area. 
Conventional cooling techniques to induce whole body 
hypothermia include surface cooling using circulating 
cold water or fanned cold air, alcohol baths, icepacks, 
cold water gastric, bladder lavage, ice‑water immersion, 
and cooling blankets. However, these techniques 
consume a significant amount of time to achieve the 
target temperature. Because of the apparent drawbacks 
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of surface cooling methods, investigators have examined 
alternative cooling techniques including endovascular 
catheters inserted via the femoral vein in the inferior vena 
cava. Clinical pilot studies in stroke patients show that 
these catheters provide rapid and precise temperature 
control.[18] A separate series of randomized clinical 
trials (Induction of Cooling; iCOOL) are underway where 
different devices including the Rhinochill, a noninvasive 
intranasal cooling catheter, are being studied. At present, 
three iCOOL studies are underway to investigate more 
rapid means to initiate therapeutic hypothermia for 
ischemic stroke patients. These studies are comparing the 
feasibility, safety, and efficacy of such methods to help 
initiate the therapeutic hypothermia process in the field 
for patients with stroke or after cardiac arrest.[42]
Complications
Hypothermia is not a complication‑free modality. 
Cardiovascular compromise, including decreased heart 
rate, myocardial infarctions, other arrhythmias such as 
atrial fibrillation, and reduced cardiac output, has been 
recorded in previous hypothermia studies.[5] Platelet 
dysfunction and alterations of coagulation enzyme activity 
during hypothermia have been recorded.[2] Therapeutic 
hypothermia is also reportedly associated with decreased 
urine output and can cause metabolic problems such 
as hypokalaemia. ICTuS-L showed increased incidence 
of pneumonia in the hypothermic group. While several 
studies, including the COOL AID II study, have shown 
no significant difference in serious complications 
during therapeutic hypothermia, shivering as well as 
intolerance to induced hypothermia (even mild), have 
been consistently reported. Cardiogenic shock, pulmonary 
edema, and deep venous thrombosis have also been 
reported in hypothermic patients, however, several 
confounding variables coexist for these complications.
CONCLUSION
The American Stroke Association is predicting the 
prevalence of stroke to increase in the coming decades. 
Interventional techniques such as endovascular clot 
retrieval for the treatment of acute ischemic stroke 
have proved to be effective in reducing the morbidity 
and mortality of stroke. In addition to such practices, a 
novel technique such as therapeutic hypothermia may 
be effective in improving patient outcomes. Early clinical 
trials such as COOL AID and ICTuS have lent support 
to its safety and feasibility; however, more evidence is 
needed to help prove its use in clinical practice.
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